Triazolam

Halcion (triazolam) is a small molecule pharmaceutical. Triazolam was first approved as Halcion on 1982-11-15. It is used to treat sleep initiation and maintenance disorders in the USA. The pharmaceutical is active against gamma-aminobutyric acid receptor subunit alpha-3, gamma-aminobutyric acid receptor subunit alpha-2, gamma-aminobutyric acid receptor subunit alpha-1, and gamma-aminobutyric acid receptor subunit alpha-5.